

The neutrophil gelatinase-associated lipocalin (NGAL), a NF- κ B-regulated gene, is a survival factor for thyroid neoplastic cells

Alessio Iannetti^{*†}, Francesco Pacifico^{††}, Renato Acquaviva^{*}, Alfonso Lavorgna^{*}, Elvira Crescenzi[‡], Carlo Vascotto[§], Gianluca Tell[§], Anna Maria Salzano[¶], Andrea Scalonì[¶], Emilia Vuttariello^{||}, Gennaro Chiappetta^{||}, Silvestro Formisano^{*}, and Antonio Leonardi^{*.***}

^{*}Dipartimento di Biologia e Patologia Cellulare e Molecolare, "Federico II" University of Naples, via S. Pansini 5, 80131 Naples, Italy; [†]Istituto di Endocrinologia ed Oncologia Sperimentale, via S. Pansini 5, 80131 Naples, Italy; [‡]Dipartimento di Scienze e Tecnologie Biomediche, University of Udine, Piazzale Kolbe 4, 33100 Udine, Italy; [¶]Laboratorio di Proteomica e Spettrometria di Massa, Istituto per il Sistema Produzione Animale in Ambiente Mediterraneo, Consiglio Nazionale delle Ricerche, via Argine 1085, 80147 Naples, Italy; and ^{||}Istituto Nazionale Tumori "Fondazione G. Pascale", via M. Semmola, 80131 Naples, Italy.

Edited by Guido Franzoso, Imperial College, United Kingdom, and accepted by the Editorial Board June 25, 2008 (received for review November 15, 2007)

NF- κ B is constitutively activated in primary human thyroid tumors, particularly in those of anaplastic type. The inhibition of NF- κ B activity in the human anaplastic thyroid carcinoma cell line, FRO, leads to an increased susceptibility to chemotherapeutic drug-induced apoptosis and to the blockage of their ability to form tumors in nude mice. To identify NF- κ B target genes involved in thyroid cancer, we analyzed the secretome of conditioned media from parental and NF- κ B-null FRO cells. Proteomic analysis revealed that the neutrophil gelatinase-associated lipocalin (NGAL), a protein involved in inflammatory and immune responses, is secreted by FRO cells whereas its expression is strongly reduced in the NF- κ B-null FRO cells. NGAL is highly expressed in human thyroid carcinomas, and knocking down its expression blocks the ability of FRO cells to grow in soft agar and form tumors in nude mice. These effects are reverted by the addition of either recombinant NGAL or FRO conditioned medium. In addition, we show that the prosurvival activity of NGAL is mediated by its ability to bind and transport iron inside the cells. Our data suggest that NF- κ B contributes to thyroid tumor cell survival by controlling iron uptake via NGAL.

Cancer is a multistep process during which cells undergo alterations of their normal functions that progressively lead to the genesis of a tumor. Among the most significant changes, cancer cells begin to secrete, into the tumor microenvironment, a number of factors that stimulate their own growth/survival and mediate angiogenesis and metastasis. During the last years, the role of NF- κ B in the pathogenesis of human cancer has strongly emerged. In particular, because it is now generally accepted that chronic inflammation contributes to the genesis of many solid tumors, such as gastric, colon, or hepatic carcinomas, it has been recently shown that activation of NF- κ B by the classical IKK β -dependent pathway is a crucial mediator of inflammation-induced tumor growth and progression in animal models of inflammation-associated cancer (1, 2). This is not particularly surprising given that NF- κ B controls expression of a number of proinflammatory factors (cytokines, chemokines, and growth factors), secreted by cancer cells in the tumor microenvironment, that substantially contribute to tumor development (3, 4). Understanding the molecular mechanism by which these factors play their role in cancer could help in the comprehension of the role of NF- κ B in inflammation-related cancer and could open innovative perspectives in the treatment of tumors.

We have shown that NF- κ B is strongly activated in human anaplastic thyroid carcinomas (ATCs) (5). To study the role of NF- κ B in thyroid cancer, we inhibited its function by stably transfecting FRO cells (derived from a human ATC) with a super-repressor form of I κ B α (I κ B α M). As a result, FRO

I κ B α M cells lost their oncogenic potential mainly from an increased susceptibility to drug-induced apoptosis (5).

The neutrophil gelatinase-associated lipocalin (NGAL), also known as lipocalin-2, is a member of a large family of lipocalins, a group of small extracellular proteins with great functional diversity (6). It is released from neutrophil granules as a 25-kDa monomer, a 46-kDa disulfide-linked homodimer, and a 135-kDa disulfide-linked heterodimer with a matrix metalloproteinase-9 (MMP-9) (7). NGAL is thought to be an acute phase protein (8) whose expression is up-regulated in human epithelial cells under different inflammatory conditions, such as inflammatory bowel disease (9). Elevated NGAL expression has also been shown in different human tumors including breast (10), lung (11), colon (9), ovary (12), and pancreas (13) carcinomas. However, the precise role of NGAL has not been well defined. Several studies have suggested that NGAL is a potent bacteriostatic agent that has siderophore-mediated sequestering of iron (14, 15), and that it is capable of protecting MMP-9 from autodegradation, thereby favoring the metastatic potential of cancer cells (16). As a secreted binding protein, it has been reported that the murine ortholog, 24p3, plays a crucial role in IL-3 deprivation-induced apoptosis by regulating intracellular iron delivery, very likely after interaction with a 24p3 receptor (17). Indeed, the human NGAL protects A459 and MCF7 cells from apoptosis induced by PDK1 inhibitors (18). Last, NGAL induces cell proliferation by promoting the iron-dependent metabolism of nucleotides for DNA synthesis (19).

The cellular system FRO/FRO I κ B α M represents an excellent model for the identification of NF- κ B-regulated factors that, when secreted in the extracellular milieu, could play a role in thyroid cancer. Thus, we used a different proteomic approach to analyze the pattern of expression of secreted proteins from conditioned medium of parental FRO cells and FRO I κ B α M clones. One of the proteins that showed a marked decrease of expression in FRO I κ B α M cells was NGAL. We show that knocking down NGAL expression blocks the ability of FRO cells to form colonies in soft agar and tumors in nude

Author contributions: A. Leonardi designed research; A.I., F.P., R.A., A. Lavorgna, E.C., C.V., A.M.S., and E.V. performed research; F.P., G.T., A.S., G.C., and S.F. analyzed data; and F.P. and A. Leonardi wrote the paper.

The authors declare no conflict of interest.

This article is a PNAS Direct Submission. G.F. is a guest editor invited by the Editorial Board.

[†]A.I. and F.P. contributed equally to this work.

^{***}To whom correspondence should be addressed. E-mail: leonardi@unina.it

This article contains supporting information online at www.pnas.org/cgi/content/full/0710846105/DCSupplemental.

© 2008 by The National Academy of Sciences of the USA




Fig. 2. Inhibition of NGAL expression by siRNA and *in vitro* oncogenic activity of the siRNA clones. The expression of NGAL in FRO cells, stably transfected with either siRNA plasmids (2/2, 2/6), control siRNA plasmid (220/22), or empty vector (Neo), was determined by Western blot analysis on total cell lysates (A) and on conditioned media (B). (C) Colony formation assay. Colonies >50 cells were scored after 2 weeks incubation at 37°C (D). Magnification: $\times 200$. *, $P < 0.0001$ (2/2 and 2/6 vs. FRO, FRO-Neo, and 220/22).

(indicated as siRNA NGAL 220/22). Fig. 2B shows the levels of secreted NGAL. These clones were tested for their ability to grow in semisolid medium and to form tumors in nude mice. In *in vitro* experiments, whereas FRO, FRO Neo, and 220/22 cells gave rise to foci of transformation, 2/2 and 2/6 clones did not form any colonies (Fig. 2C and D). In *in vivo* assays, the injection of parental FRO or 220/22 cells into nude mice induced tumor




Fig. 3. NGAL protects FRO cells from apoptosis induced by serum-withdrawal. 2.5×10^5 cells per well were seeded in 6-well culture plates and grown either in the presence of serum (+S), in the absence of serum (-S), or in serum-free conditioned medium from FRO cells (-S + CM). Cell death was assessed by propidium iodide staining (A) and by Western blot analysis (B). Results were mean \pm SD of at least three separate experiments. **, $P < 0.0005$; ***, $P < 0.0001$.

formation in 12 of 12 mice, whereas the injection of 2/2 or 2/6 cells induced tumor formation in 1 of 6 and 4 of 6 mice, respectively (Table 2). The tumors developed from 2/2 and 2/6 cells were 4-fold and 2-fold smaller than those formed after injection of parental cells, respectively (Table 2). Notably, 2 of 4 tumors from 2/6 cells showed NGAL staining after immunohistochemical analysis, indicating that the expression of the siRNA plasmid was lost. We also blocked NF- κ B in FRO cells by transient overexpression of I κ B α M. In the absence of functional NF- κ B, FRO cells did not form colonies in soft agar. Reexpression of NGAL partially rescued the ability of FRO cells to form colonies in soft agar (Fig. S3A-C).

NGAL Is a Survival Factor in FRO Cells. We analyzed the response of parental FRO cells and NGAL siRNA clones to serum withdrawal-induced apoptosis. All clones grown in the presence of serum showed 2–3% apoptosis, as assessed by propidium iodide staining (Fig. 3A). Serum deprivation did not affect the survival of FRO, FRO Neo, and 220/22 clones but induced a significant cell death (10–15%) in 2/2 and 2/6 clones (Fig. 3A). This effect was reverted by the addition of the conditioned medium of either

Table 2. *In vivo* tumor growth induced by FRO Neo cells and FRO siRNA NGAL clones

Cell type	Tumor incidence	Tumor volume average, cm ³	Tumor weight average, g
FRO	6/6	0.37 \pm 0.04	0.24 \pm 0.05
FRO siRNA NGAL 2/2	1/6	0.01***	0.05***
FRO siRNA NGAL 2/6	4/6	0.16 \pm 0.06**	0.11 \pm 0.02**
FRO siRNA NGAL 220/22	6/6	0.33 \pm 0.02	0.21 \pm 0.03

2×10^7 cells were injected s. c. on a flank of each 6-week-old nude mouse. Tumor weight, diameter, and volume values were measured and determined as described in the S1 Text. Two of four tumors developed by mice injected with FRO siRNA 2/6 cells showed partial NGAL staining after immunohistochemical analysis. ***, $P < 0.0001$ (FRO 2/2 vs. FRO); **, $P < 0.001$ (FRO 2/6 vs. FRO).




Fig. 5. Intracellular iron content of the different FRO cell lines. Colorimetric analysis of intracellular iron concentration is shown. Results were mean \pm SD of at least three separate experiments, performed in triplicate. Significantly different from controls. *, $P < 0.05$.

Because these results indicated that the intracellular iron content could be relevant for the survival of FRO cells, we analyzed the intracellular iron concentration of parental FRO cells and NGAL siRNA clones (Fig. 5). The colorimetric assay showed that 2/2 and 2/6 clones lacked at least 20–30% of iron content ($P < 0.05$) compared with FRO, FRO Neo, and 220/22 cells, thus suggesting that the absence of NGAL determined a decrease of iron uptake in the clones.

Discussion

We have identified NGAL as a mediator of the NF- κ B oncogenic activity in thyroid cancer. NGAL is highly expressed in the human thyroid carcinoma FRO cell line and other poorly differentiated thyroid cancer cell lines (Fig. 1A and data not shown), is highly expressed in primary human ATC (Fig. 1B–E and Table 1), and acts as a survival factor for thyroid cancer cells (Figs. 3 and 4). The prosurvival activity of NGAL is mediated by its ability to bind iron and to transport it inside the cells (Figs. 4 and 5). These findings show that NGAL is a critical effector of NF- κ B-mediated oncogenic activity, defines a prosurvival function of NGAL, and highlights iron as a central controller of cell survival.

Various types of cancers express high levels of NGAL, including colon, pancreas, breast, bladder, and liver (9–13). NGAL represents the human homolog of the rat neu-related lipocalin, a gene that was shown to be overexpressed in HER-2/neu oncogene-induced rat mammary tumors (23). Whether NGAL is causal or contributory to cancer is unknown. It has been reported that NGAL is a surviving factor for cancer cells. Ectopic expression of NGAL in lung and breast cancer cell lines reduced the apoptosis that was induced by a PDK1 inhibitor whereas the decreased expression of NGAL by siRNA had opposite effects (18). Our results confirm that NGAL is a surviving factor for cancer cells, and we extend these findings by demonstrating that the protective effect of NGAL is mediated by its ability to bind and transport iron. Our results are in agreement with the model proposed by Devireddy *et al.* (17). In this model, it is proposed that internalization of the apo form of NGAL leads to iron loss and apoptosis. Conversely, internalization of iron-loaded NGAL might prevent apoptosis.

Iron contributes to enzyme activity in DNA synthesis, metabolism, and oxygen response, and its acquisition plays a critical role in development, cell growth, and survival (22). Cancer cells have a higher requirement for iron than normal cells because they rapidly proliferate. This is reflected by the evidence that tumor cells have higher numbers of transferrin receptors on their surface, mediating a high rate of iron uptake (24). The importance of keeping the levels of iron uptake constant is further

suggested by the evidence that multiple and redundant systems for iron uptake and transport exist. Most cells acquire iron by capturing iron-loaded transferrin. However, hypotransferrinemic mice (25, 26) and humans (27) have defects in central nervous system development and hematopoiesis when most epithelial organs are normal. Likewise, the mice lacking the transferrin receptor 1 initiate organogenesis but succumb to the effects of anemia (28). Given that iron is necessary for all of the cells, there must be other pathways for iron acquisition in epithelial cells. One such pathway is mediated by NGAL. In our experimental model, we observed that cells knocked down for NGAL expression showed a decrease of \approx 20–30% iron content, and that this decrease still allowed cell survival. However, whether either the iron delivery was further decreased or cells were exposed to an appropriate stress, such as serum deprivation, cells underwent apoptosis. Indeed, administration of iron, either as iron salt, transferrin, or iron-loaded NGAL, restored the ability of knockdown cells to survive in the absence of serum. Similarly, NGAL knockout mice are vital and do not show gross developmental defects, although they succumb to bacterial infection (29).

Many studies have demonstrated that iron chelators, such as DFO, have effective anticancer activity (30). Iron is essential for the catalytic activity of ribonucleotide reductase (an enzyme mediating the conversion of all four ribonucleotides to their deoxyribonucleotide counterparts), which is the rate-limiting step of DNA synthesis (31). However, in our experimental system, the proliferation rate of the cells knocked down for NGAL expression is not affected (data not shown).

Iron levels strictly control the activity of specific prolyl hydroxylase-domain enzymes (PHDs), which, in turn, promote functional activation of transcription factors involved in tumor development, as is the case of the HIF-1, which controls genes involved in energy metabolism and angiogenesis (32). HIF-1 is primarily regulated by specific PHDs that initiate its degradation via the von Hippel-Lindau tumor suppressor protein. The oxygen and iron dependency of PHD activity accounts for regulation of the pathway by both cellular oxygen and iron status. We have evidence that in our experimental system, the protein level of HIF-1 α is increased in the NGAL knockdown clones and is down-regulated by the addition of iron. Conversely, in control cells, the level of HIF-1 α protein is low and up-regulated by the addition of DFO. Moreover, the activity of a HIF1-responsive promoter parallels the level of HIF-1 protein (A.I., F.P., and A. Leonardi, unpublished observation). Because NF- κ B is a central component in the hypoxic response that positively regulates HIF-1 α expression (33), it is tempting to speculate that the involvement of NGAL as an iron transporter, and its opposing effect on HIF-1 α expression, could be a part of an autoregulatory loop that has inhibitory function between NF- κ B and HIF-1 to control tumor progression.

Modulation of cell survival may not be the only way NGAL influences the behavior of a cancer cell. NGAL has been demonstrated to form a complex with MMP-9, playing a role in the maintenance of an extracellular pool of a potentially active form of the protease, whose activity is associated with angiogenesis and tumor growth (16). This is supported by the evidence that the level of NGAL expression correlates with the clinical outcome of the patients and the depth of the tumor invasion (17). We have evidence that a complex between NGAL and MMP-9 also exists in transformed thyroid cells, although neither the exact role that such a complex plays in thyroid cancer, nor whether or not the activity of MMP-9 is affected by the presence of NGAL, is known (A.I. and A. Leonardi, unpublished observations).

In other experimental systems, NGAL has been shown to induce expression of E-cadherin to promote formation of polarized epithelia and diminish invasiveness of ras-transformed

cell lines (34). In our experimental system, NGAL seems to have a different role. In fact, ectopic expression of NGAL in a normal thyroid cell line, or its knockdown in transformed cells, does not alter the expression of E-cadherin or vimentin (data not shown).

Our results, in addition to identifying NGAL as a potential target for therapeutic intervention, also strengthen the rationale for the use of iron chelators in the treatment of cancer. Depleting iron from a rapidly dividing cancer cell through the implementation of iron chelators, or decreasing NGAL expression, deprives iron of a component critical for various cellular processes and induces apoptosis.

1. Greten FR, et al. (2004) IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. *Cell* 118:285–296.
2. Pikarsky E, et al. (2004) NF-kappaB functions as a tumour promoter in inflammation-associated cancer. *Nature* 431:461–466.
3. Karin M (2006) Nuclear factor-kappaB in cancer development and progression. *Nature* 441:431–436.
4. Lin WW, Karin M (2007) A cytokine-mediated link between innate immunity, inflammation, and cancer. *J Clin Invest* 117:1175–1183.
5. Pacifico F, et al. (2004) Oncogenic and anti apoptotic activity of NF-kB in human thyroid carcinomas. *J Biol Chem* 279:54610–54619.
6. Flower DR, North AC, Sansom CE. (2000) The lipocalin protein family: Structural and sequence overview. *Biochim Biophys Acta*. 1482:9–24.
7. Kjeldsen L, Johnsen AH, Sengelov H, Borregaard N (1993) Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. *J Biol Chem* 268:10425–10432.
8. Nilsen-Hamilton M, et al. (2003) Tissue involution and the acute phase response. *Ann N Y Acad Sci* 995:94–108.
9. Nielsen BS, et al. (1996) Induction of NGAL synthesis in epithelial cells of human colorectal neoplasia and inflammatory bowel diseases. *Gut* 38:414–420.
10. Stoesz SP, et al. (1998) Heterogeneous expression of the lipocalin NGAL in primary breast cancers. *Int J Cancer* 79:565–572.
11. Friedl A, Stoesz SP, Buckley P, Gould MN (1999) Neutrophil gelatinase-associated lipocalin in normal and neoplastic human tissues. Cell type-specific pattern of expression. *Histochem J* 31:433–441.
12. Bartsch S, Tschesche K (1995) Cloning and expression of human neutrophil lipocalin cDNA derived from bone marrow and ovarian cancer cells. *FEBS Lett* 357:255–259.
13. Furutani M, Arai S, Mizumoto M, Kato M, Imamura M (1998) Identification of a neutrophil gelatinase-associated lipocalin mRNA in human pancreatic cancers using a modified signal sequence trap method. *Cancer Lett* 122:209–214.
14. Goetz DH, et al. (2002) The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. *Mol Cell* 10:1033–1043.
15. Flo TH, et al. (2004) Lipocalin 2 mediates an innate immune response to bacterial infection by sequestering iron. *Nature* 432:917–921.
16. Fernández CA, et al. (2005) The matrix metalloproteinase-9/neutrophil gelatinase-associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients. *Clin Cancer Res* 11:5390–5395.
17. Devireddy LR, Gazin C, Zhu X, Green MR (2005) A cell-surface receptor for lipocalin 24p3 selectively mediates apoptosis and iron uptake. *Cell* 123:1293–1305.
18. Tong Z, et al. (2005) Neutrophil gelatinase-associated lipocalin as a survival factor. *Biochem J* 391:441–448.
19. Le NT, Richardson DR (2002) The role of iron in cell cycle progression and the proliferation of neoplastic cells. *Biochim Biophys Acta* 1603:31–46.
20. Cowland JB, Sorensen OE, Sehested M, Borregaard N (2003) Neutrophil Gelatinase Associated Lipocalin is up-regulated in human epithelial cells by IL-1 β , but not TNF- α . *J Immunol* 171:6630–6639.
21. Cowland JB, Muta T, Borregaard N (2006) Neutrophil Gelatinase Associated Lipocalin is controlled by I κ B ζ . *J Immunol* 176:5559–5566.
22. Dunn LL, Rahmanto YS, Richardson DR (2007) Iron uptake and metabolism in the new millennium. *Trends Cell Biol* 17:93–100.
23. Stoesz SP, Gould MN (1995) Overexpression of neu-related lipocalin (NRL) in neu-initiated but not ras or chemically initiated rat mammary carcinomas. *Oncogene* 11:2233–2241.
24. Richardson DR, Ponka P (1997) The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells. *Biochim Biophys Acta* 1331:1–40.
25. Huggenvik JI, et al. (1989) A splicing defect in the mouse transferrin gene leads to congenital atransferrinemia. *Blood* 74:482–486.
26. Trenor CC, III, Campagna DR, Sellers VM, Andrews NC, Fleming MD (2000) The molecular defect in hypotransferrinemic mice. *Blood* 96:1113–1118.
27. Hayashi A, Wada Y, Suzuki T, Shimizu A (1993) Studies on familial hypotransferrinemia: Unique clinical course and molecular pathology. *Am J Hum Genet* 53:201–213.
28. Levy JE, Jin O, Fujiwara Y, Kuo F, Andrews NC (1999) Transferrin receptor is necessary for development of erythrocytes and the nervous system. *Nat Genet* 21:396–399.
29. Berger T, et al. (2006) Lipocalin 2-deficient mice exhibit increased sensitivity to Escherichia coli infection but not to ischemia-reperfusion injury. *Proc Natl Acad Sci USA* 103:1834–1839.
30. Buss JL, Torti FM, Torti SV (2003) The role of iron chelation in cancer therapy. *Curr Med Chem* 10:1021–1034.
31. Richardson DR (2005) Molecular mechanisms of iron up-take by cells and the use of iron chelators for the treatment of cancer. *Curr Med Chem* 12:2711–2729.
32. Semenza G (2001) HIF-1, O₂, and the 3 PHDs: How animal cells signal hypoxia to the nucleus. *Cell* 107:1–3.
33. Rius J, et al. (2008) NF-kB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1 α . *Nature* 453: 807–811.
34. Hanai J, et al. (2005) Lipocalin 2 diminishes invasiveness and metastasis of Ras-transformed cells. *J Biol Chem* 280:13641–13647.

Materials and Methods

Cell cultures and biological reagents, processing of conditioned media, two-dimensional gel electrophoresis, mass spectrometry analysis, immunohistochemical analysis, Northern and Western blot experiments, *in vitro* and *in vivo* tumorigenicity assays, measurements of apoptosis, quantification of iron content, and statistical analysis were performed as described in the *SI Text*.

ACKNOWLEDGMENTS. This work was supported by Ministero dell'Istruzione, dell'Università e della Ricerca, Fondo per gli Investimenti della Ricerca di Base Grant RBRN07BMCT (to G.T.) and a grant from the Associazione Italiana Ricerca sul Cancro (A.L.).